Patient survey currently underway
in partnership with the HealthTree Foundation;
data expected in Q1 2025
TEL
AVIV, Israel and WALTHAM,
Mass., Sept. 17, 2024 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a
commercial stage biopharmaceutical company pursuing life-changing
therapies in oncology and rare diseases, today announced the launch
of
Mobilization Matters, a digital resource
for people with multiple myeloma who are preparing for stem
cell collection for an autologous stem cell transplant. Launched on
Apheresis Awareness Day, this platform offers patient stories,
educational resources, and more to support those undergoing this
critical phase of treatment.
In conjunction with this launch, BioLineRx is partnering
with the HealthTree Foundation to conduct the Mobilization
Matters Stem Cell Collection Survey. This initiative aims to
gather insights from patients
about their experiences with stem cell
collection and apheresis as part of their multiple
myeloma journey. The findings will help illuminate patient
experiences, enhance understanding, and improve care and support
strategies. Survey results are expected in Q1 2025.
"We are deeply committed to supporting multiple myeloma patients
and their care partner through their stem cell collection process,"
said Holly May, MBA,
President of BioLineRx USA. "Our
goal is to enrich education and foster dialogue, empowering
patients with knowledge. Mobilization Matters is
designed to achieve this by amplifying patient voices and providing
comprehensive resources."
In addition to patient stories
and survey information, Mobilization Matters
features a discussion
guide to facilitate conversations between
patients and their healthcare teams before apheresis.
For more information, visit www.mobilizationmatters.com.
About the Mobilization Matters Survey
The Mobilization Matters Stem Cell Collection Survey
is being conducted by the HealthTree Foundation on behalf of
BioLineRx among adults with multiple myeloma (ages 18+) who have
attempted stem cell collection for a planned
transplant. Developed in collaboration with experts
from leading institutions and patient advisors, the survey aims to
provide valuable insights into the emotional, physical, and daily
life challenges patients face during the stem cell collection
process. Results will be shared on mobilizationmatters.com, once
available.
"This survey will provide important insights into the patient
experience with stem cell collection, offering a deeper
understanding of the potential challenges involved," said
Beth B. Giblin, PharmD, Head
of US Medical Affairs, BioLineRx. "Our aim is to use the findings
to build on the existing literature and inform data-driven
approaches to patient care and support."
"We need to better understand the patient's journey during the
stem cell collection process," said Jenny Ahlstrom, Founder & CEO of the
HealthTree Foundation. "We are excited to use these data to advance
education and drive patient-centered care. This collaboration
supports our mission to empower multiple myeloma patients with
knowledge, enhance their care experiences, and contribute
meaningfully to research."
This survey marks the first patient experience study by the
HealthTree Foundation on this critical topic.
The research is being conducted through the HealthTree Cure Hub, a patient-data
platform and community with over 14,000 registered myeloma
patients, where participants can opt into surveys and studies to
accelerate research and shape the future of healthcare.
About Stem Cell Mobilization for Multiple Myeloma
Autologous stem cell transplantation (ASCT) is the preferred first-line treatment for multiple
myeloma – the second most common blood cancer – and is integral to
the prospect of improving survival and helping to restore the
immune system.i,ii
Prior to ASCT, patients undergo apheresis, a procedure to
collect stem cells for transplant. Stem cells
are made deep in the bone marrow
and need to be mobilized from the bone marrow
to the bloodstream for collection during
apheresis.iii,iv
ASCT success depends on adequate mobilization and collection of
stem cells.iii While more multiple myeloma patients
are candidates for ASCT than ever before, stem cell mobilization
and collection is a growing challenge. This is due to factors
such as increasing proportion of
older patients receiving ASCTvi
and the use of standard 3- and 4-drug
induction therapy, which can further impair mobilization
with fewer cells mobilized and additional days of apheresis
required.vii, viii
About the HealthTree Foundation
HealthTree is a global nonprofit using innovation to save lives.
They provide lifetime personalized support and education,
meaningful patient-to-patient connections and a powerful patient
data portal. HealthTree's cutting-edge technology empowers patients
to better manage their health and engages them as critical
contributors to lifesaving research. The trust of their patient
community allows HealthTree to provide continually updated,
real-world patient data to researchers who seek to advance clinical
care and find cures for blood cancers. Visit healthtree.org
today.
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage
biopharmaceutical company pursuing life-changing therapies in
oncology and rare diseases. Since receiving approval for our first
marketed product in the U.S., BioLineRx is continuing to advance a
pipeline of investigational drugs for patients
with sickle cell disease, pancreatic cancer, and other solid
tumors. Headquartered in Israel,
and with operations in the U.S., the company is driving innovative
therapeutics with end-to-end expertise in development and
commercialization, ensuring life-changing discoveries move beyond
the bench to the bedside.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or
on Twitter and LinkedIn.
Logo:
https://mma.prnewswire.com/media/2154863/4858892/BioLineRx_Ltd_Logo.jpg
i Dhakal B, et al. Transplant Cell Ther.
2022;28(6):284-293.
ii Kumar SK, et al.
Blood. 2008;111(5):2516-2520.
iii
Giralt S, Costa L, Schriber J, et al. Biol Blood Marrow
Transplant. 2014;20(3):295-308.
iv
American Cancer Society. Types of Stem Cell and Bone Marrow
Transplants.
v Swan D, Hayden PJ, Eikema
D-J, et al. BR J Haematol. 2022;197(1):82-96.
vi Morris CL, Siegel E, Barlogie B, et al. Br J
Haematol. 2003;120(3):413-423.
vii
Hulin C, Offner F, Moreau P, et al. Haematologica.
2021;106(8):2257-2260.
viii Chhabra S,
Callander N, Watts NL, et al. Transplant Cell Ther.
2023;29(3):174.e1-174.e10.
CONTACTS:
United
States
John Lacey
BioLineRx
IR@biolinerx.com
View original
content:https://www.prnewswire.com/news-releases/biolinerx-launches-mobilization-matters-a-digital-resource-for-people-with-multiple-myeloma-preparing-for-stem-cell-collection-302250690.html
SOURCE BioLineRx Ltd.